Dr Maria De Santis from the Kaiser Franz Josef Hospital, Vienna, Austria talks to ecancertv at ASCO GU congress 2014 about the state of play for CPRC treatment and what the future might hold.
She covers results announced at ASCO GU such as the phase III PREVAIL trial looking at enzalutamide and answers questions submitted by ecancer members.
The video looks at:
- Potential clinical strategies to overcome androgen resistance
- What treatment options are available for patients with CRPC
- Sequencing for the use of newly available drugs for the management of CRPC
This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).